Suppr超能文献

急性髓系白血病伴中枢性尿崩症

Acute myeloid leukemia with central diabetes insipidus.

作者信息

Ladigan Swetlana, Mika Thomas, Figge Anja, May Annette M, Schmiegel Wolff, Schroers Roland, Baraniskin Alexander

机构信息

Department of Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum, Germany; Center of Clinical Research, Department of Molecular GI-Oncology, Ruhr-University Bochum, Germany.

Department of Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum, Germany; Center of Clinical Research, Department of Molecular GI-Oncology, Ruhr-University Bochum, Germany.

出版信息

Blood Cells Mol Dis. 2019 May;76:45-52. doi: 10.1016/j.bcmd.2019.01.005. Epub 2019 Jan 24.

Abstract

While acute myeloid leukemia (AML) is the most common type of acute leukemia in adulthood, the constellation of AML associated with central diabetes insipidus (CDI) is rare and typically occurs in patients with chromosome 3 or 7 abnormalities. This subgroup of AML is associated with a poor clinical outcome. In this report, we present a young woman with AML and concurrent CDI in the presence of inversion(3)(q21q26). The AML was refractory to the induction therapy "7 + 3". Afterwards, the patient underwent allogenic stem cell transplantation (alloHSCT) and is still remaining in complete remission (CR) from AML as well as CDI 440 days after alloHSCT. Subsequently, in the largest study concerning patients with AML and CDI reported so far, we discuss additional cases from the literature. We demonstrated that patients with AML and CDI belong to the adverse prognostic group and clearly benefit from alloHSCT.

摘要

虽然急性髓系白血病(AML)是成人中最常见的急性白血病类型,但与中枢性尿崩症(CDI)相关的AML情况罕见,且通常发生在有3号或7号染色体异常的患者中。这一亚组的AML与不良临床结局相关。在本报告中,我们介绍了一名年轻女性,她患有AML并伴有3号染色体倒位(3)(q21q26),同时并发CDI。该AML对诱导治疗“7+3”耐药。之后,患者接受了异基因干细胞移植(alloHSCT),在alloHSCT后440天,AML及CDI仍处于完全缓解(CR)状态。随后,在迄今为止关于AML和CDI患者的最大规模研究中,我们讨论了文献中的其他病例。我们证明,AML和CDI患者属于不良预后组,明显受益于alloHSCT。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验